Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

Patients with coronary heart disease or equivalent risk received a single dose of 30, 100, 300, or 500 mg of unformulated D-4F (n = 8, each dose) or placebo (n = 8) under fasting conditions. An additional 10 patients received 500 mg (n = 8) or placebo (n = 2) with a low-fat meal. There were no signi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bloedon, LeAnne T., Dunbar, Richard, Duffy, Danielle, Pinell-Salles, Paula, Norris, Robert, DeGroot, Bruce J., Movva, Rajesh, Navab, Mohamad, Fogelman, Alan M., Rader, Daniel J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Biochemistry and Molecular Biology 2008
Materias:
Patient-Oriented and Epidemiological Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2386905/
https://ncbi.nlm.nih.gov/pubmed/18323573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.P800003-JLR200
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares